Leveraging External Data Through Bayesian Approaches

This chapter first outlines the FDA’s interpretation of “substantial evidence” as necessitating multiple well-controlled clinical trials, a standard that has remained unchanged despite the evolving landscape of drug development, which now includes a focus on serious and rare diseases as well as precision medicine. The chapter also discusses the shift towards incorporating Bayesian statistics in treatment effect evaluations, a method that allows for the inclusion of prior knowledge and has become increasingly feasible with the advent of advanced computing. Key differences between Bayesian and frequentist approaches, the use of external data, and the role of Bayesian methodology in adaptive design and safety signal detection are explored. The chapter aims to bridge the gap between theory and practical application in clinical trials, emphasizing the importance of transparency in assumptions and the flexibility afforded by Bayesian methods in various stages of trial design and analysis. The organization of the chapter covers a high-level comparison between Bayesian and frequentist methodologies, delves into Bayesian techniques, presents successful case studies, and concludes with a discussion on the implications for future drug development and regulatory decisions.